Novel peptide vaccine promising in myeloid leukemia

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 5
Volume 17
Issue 5

ATLANTA-In a phase I/II randomized trial, a novel leukemia vaccine, PR1 peptide, produced immune responses that correlated with a longer event-free survival.

ATLANTA-In a phase I/II randomized trial, a novel leukemia vaccine, PR1 peptide, produced immune responses that correlated with a longer event-free survival. Responses were durable in high-risk patients with leukemia who had failed prior therapy. Muzaffar H. Qazilbash, MD, of M.D. Anderson Cancer Center, presented the findings at ASH 2007 (abstract 283).

PR1 is an HLA-A2–restricted peptide derived from the myeloid leukemia-associated antigens proteinase 3 and neutrophil elastase.

“These proteins are overexpressed or variably expressed in leukemias and can potentially serve as a good target for the immune system,” Dr. Qazilbash said.
The current trial enrolled 66 HLA-A2+ patients with AML (n = 42), CML (n = 13), or myelodysplastic syndromes (n = 11). Of these patients, 53 had active disease and 13 were in remission.

The first 9 patients were entered onto the phase I portion, while the remaining were randomized to one of three PR1 dose levels, along with GM-CSF. The initial 54 patients received three vaccinations, while the last 12 received six vaccinations.

Immune responses to the vaccine occurred in 25 of 53 (47%) patients who had measurable disease. Clinical responses were seen in 9 of 25 (36%) patients who exhibited an immune response vs 3 of 28 (10%) nonresponders (P = .01).

Immune responders had longer event-free survival than nonresponders (8.7 months vs 2.4 months, P = .03) and a trend toward improved overall survival (not yet reached vs 17 months).

Four of the 13 patients in complete remission have experienced long-term remission for a median of 30.5 months (range, 11 to 59 months). Immune responses have been maintained for as long as 4 years in some patients. “The best responders were those with relatively low-volume disease (< 10% of leukemia blasts in the marrow) or only minimal residual disease as measured by cytogenetic and molecular analyses,” Dr. Qazilbash said.

Multivariate analysis indicated that a low number of bone marrow blasts was a significant predictor of PR1 immune response and longer event-free survival (P < .001). A phase III trial is ongoing in patients with AML in remission.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content